Is RF microneedling device demand actually growing in 2026?

InMode's Q2 2026 revenue of $95.6M beat analyst estimates by $2.5M, driven by steady U.S. device demand for RF microneedling platforms like Morpheus8 and Secret RF. This signals continued patient appetite for minimally invasive aesthetic procedures and strong device utilization among existing practices.

Should I buy a second RF microneedling device based on InMode's earnings beat?

Not automatically. While InMode's beat validates the RF microneedling market, the company also reported flat revenue and margin compression in other segments. Before investing in a second device, audit your current device's utilization rate and per-treatment margin to ensure ROI on new capital.

What does InMode's Q2 beat tell me about my Morpheus8 or Secret RF device?

InMode's beat indicates the market is absorbing supply and practices are running treatments profitably. Your device's strong performance in a beat quarter suggests the broader market remains resilient, but your own ROI depends on your specific utilization and pricing—not InMode's overall results.

Is there pricing pressure on RF microneedling devices right now?

Yes. While InMode beat revenue estimates, the U.S. device market is competitive and pricing pressure is real, as evidenced by margin compression in other segments. Confirm your per-treatment margins and competitive positioning before committing to additional capital expenditure.

How do I know if my RF microneedling device is performing well enough to justify expansion?

Calculate your current device's utilization rate (treatments per week) and per-treatment margin (revenue minus cost of goods and labor). Compare these metrics to your target ROI timeline for a new device purchase; InMode's beat validates market demand but doesn't replace your own operational metrics.

Monday, August 24, 2026 Never miss a recall or a rule change Go Pro · $20/mo →

RegulatoryAbbVie Launches Phase 2 Forehead Lines Studytoday MarketFacial Rejuvenation Market Forecast to Hit $5.66B by 20302 days ago Business & M&AAllergan Aesthetics Overhauls Loyalty Programtoday Devices & TechXERF Technology Enters Australian Market for Skin Tightening2 days ago Business & M&AEvolus Expands Estyme to Canada, Australia, New Zealandtoday MarketArm Fat Now Top Body Sculpting Concern in Singapore2 days ago Devices & TechSofwave Hits One Million Treatments Milestonetoday RegulatoryCKD Bio Pursues China Botox Approval—2027 Launch Targeted2 days ago RegulatoryRevance Wins FDA Nod for Under-Eye Injectablesyesterday MarketGLP-1 Pill Era Is Forcing Beauty Market Shiftyesterday InjectablesAEON Releases Expanded ABP-450 Botox Biosimilar Datayesterday Devices & TechUltherapy PRIME Real-Time Imaging Reshapes Midface Liftingyesterday

Devices & Tech

InMode Q2 Revenue Beats on Steady U.S. Device Demand

Q2 revenue of $95.6M exceeds FactSet estimate; U.S. market remains resilient.

By Evan at Inside MedSpa · Aug 7, 2026

1-YEAR MOVE

INMD ▲1.0%

1-year price move by ticker
Ticker	Company	1-year change
INMD	InMode Ltd.	+1.0%

InMode reported Q2 2026 revenue of $95.6 million, beating the FactSet consensus estimate of $93.1 million. The beat reflects steady U.S. demand for its RF microneedling and energy-based platforms, signaling continued patient appetite for minimally invasive aesthetic procedures.

For medspa owners, InMode's beat matters because it validates the RF microneedling market and suggests device utilization remains strong. InMode's installed base is substantial, and a beat signals that practices are running treatments and generating revenue per device. If you own an InMode platform (Morpheus8, Secret RF), the earnings confirm the market is absorbing supply.

Inside MedSpa Pro

You've reached your free articles this week.

Keep reading every article, unlock the full trackers, and get the twice-a-week intelligence brief — from $20/mo, or $200/yr (two months free). Never miss a recall or a rule change.

Every article, unlocked — no weekly limit
The full 50-state law tracker, stock & M&A watch
The twice-a-week, 2-minute intelligence brief
Recalls, FDA clearances & safety signals as they hit

See everything you get →

Cancel anytime, one click · 14-day money-back on annual

https://insidemedspa.com/article/inmode-q2-beats-steady-us-device-demand/

Discussion

Free alerts

Get flagged before it costs you.

We'll flag the moment a recall or rule change hits your practice. One email a week, one click to leave.

Free · weekly · unsubscribe anytime. Privacy.

This morning's brief · 6 AM

The free version stops here.

What today's moves mean for your margins — and exactly what to do — already went out to Pro. By the time the trade press explains it, the window to act has closed.

Go Pro · $20/mo Two minutes a morning. Cancel anytime.

Live · Market movers

STRATA Skin Sciences-50%Hims & Hers Health+6.03%Estée Lauder+6.02%Bausch Health (Solta)-5.43%The Beauty Health Company (HydraFacial)+3.65%

The full stock & M&A watch →

FDA Activity — Aesthetic Devices

Monthly 510(k) clearances vs. recalls.

510(k) clearances Recalls

FDA Activity — Aesthetic Devices — Monthly 510(k) clearances vs. recalls.
Month	510(k) clearances	Recalls
Jun '25	0	4
Jul '25	0	1
Sep '25	0	1
Oct '25	0	2
Jan '26	0	1
Feb '26	0	5
Mar '26	0	5
Apr '26	0	19
May '26	7	18
Jun '26	34	8
Jul '26	23	4
Aug '26	5	0

The 50-state regulation tracker →

Inside MedSpa Pro

By the time it's news, it's too late.

The rebate cut, the scope-of-practice bill, the competitor opening down the street — it hits your business before the trade press ever covers it. Pro gets you there first: what happened, why it touches your margins, and exactly what to do — at 6 AM, in two minutes.

Go Pro · $20/mo Never miss a recall or a rule change. Cancel anytime.

The twice-a-week intelligence brief Go Pro · $20/mo →

InMode Q2 Revenue Beats on Steady U.S. Device Demand

Share

Discussion

Leave a comment

By the time it's news, it's too late.